FIT Biotech Oy
Company release January 11, 2017 at 10.05 am EET
FIT Biotech Oy has extended the registration day for the extraordinary General Meeting on January 26, 2017
Participation in the Extraordinary General Meeting of Shareholders
Each shareholder, who is registered on January 16, 2017 in the shareholders’ register of FIT Biotech Ltd held by Euroclear Finland Ltd, has the right to participate in the Extraordinary General Meeting of Shareholders. A shareholder, whose shares are registered on his/her personal book-entry account, is registered in the shareholders’ register of FIT Biotech Ltd.
A shareholder, who wants to participate in the Extraordinary General Meeting of Shareholders, shall register for the meeting no later than January 23, 2017 at 10.00 am by giving a prior notice of participation at FIT Biotech Ltd’s ebsite http://www.fitbiotech.fi/sijoittajille/yhtiokokoukset/ilmoittautuminen-yhtiokokoukseen/ or by mail to address FIT Biotech Ltd/ Liisa Laitinen, Biokatu 8, 33520 Tampere. When giving a prior notice by mail that should arrive before abovementioned deadline.
Holders of Nominee Registered Shares
A holder of nominee registered shares has the right to participate in the Extraordinary General Meeting by virtue of such shares, based on which he/she on the record date of the Extraordinary General Meeting, i.e. on January 16, 2017, would be entitled to be registered in the shareholders’ register of FIT Biotech Ltd held by Euroclear Finland Ltd. The right to participate in the Extraordinary General Meeting requires, in addition, that the shareholder on the basis of such shares has been registered into the temporary shareholders’ register held by Euroclear Finland Ltd at the latest by January 23, 2017 at 10.00 am. As regards nominee registered shares this constitutes due registration for the Extraordinary General Meeting.
Meeting Location
The Extraordinary General Meeting of FIT Biotech on January 26, 2017, commencing at 12:00 am at the Sitra (Conference room Edison), at the address of Itämerenkatu 11-13, Helsinki. The reception of persons who have registered for the meeting will commence at 11:45 am.
FIT BIOTECH OY
Board of Directors
For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its pa-tented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include can-cer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
